Compare DexCom, Inc. (DXCM) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? DexCom, Inc. trades at $77.68 (market cap $28.06B), while ProShares UltraPro Short QQQ ETF trades at $40.51. The key difference: DexCom, Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | SQQQ | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $97.60 |
52-Week Low | $54.84 | $36.31 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $40.511, up 4.87% over the past 24 hours. The technical outlook is neutral with mixed signals from moving averages and oscillators, while support and resistance levels are tightly clustered. As a leveraged inverse ETF designed to deliver -3x the daily return of the Nasdaq-100, it carries inherent structural risks and is unsuitable for long-term holding due to daily reset mechanics that can erode value over time.
The outlook for SQQQ remains highly speculative and tactical. It may offer short-term hedging benefits against Nasdaq-100 declines but presents severe long-term erosion risks. Investors should strictly limit exposure to sophisticated, active traders who can closely monitor market timing, as its performance is entirely dependent on short-term directional bets against the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
